First Commercial Implantations of NUMEN™ Coil of MicroPort NeuroTech Successfully Completed in France

Paris, France - On April 29, the first two commercial implantations of NUMEN™ Embolization Coil (hereinafter referred to as “NUMEN™ Coil”) developed by MicroPort NeuroTech Limtied (02172.HK, hereinafter referred to as “MicroPort NeuroTech”) were successfully completed at the Rothschild Foundation Hospital, Paris, France. The operation was performed by Professor Michel Piotin and his team, and the NUMEN™ Coil was highly evaluated by experts for its drilling ability, dense packing and stable basket formation. The three NUMEN™ Coil series, NUMEN™ Frame, NUMEN™ Fill and NUMEN™ Finish, passed the HAS review by the French health technology assessment agency in April and October 2023 with medical insurance codes awarded. This significant headway signals a more affordable treatment for patients, while also improving accessibility and affordability of aneurysm embolization therapy. France is one of the key markets in Europe as one of the top ten countries in the world in terms of the volume of neurointerventional surgery. The first commercial implantation of NUMEN™ Coil completed in France marks the commercialization of MicroPort NeuroTech products in the 16th overseas country or region, and also marks the company’s successful entry into nine of the world’s TOP 10 markets for neurointerventional surgery, further demonstrating its preeminent position and widespread recognition in the international marketplace.